ACE-031, at a dose of 1mg, is presently generating substantial interest across the European continent. Early clinical trials in regions such as the Federal Republic of Germany, France, and the UK have revealed promising results in treating particular nervous system ailments. Regulatory bodies across the region are closely reviewing the data for … Read More